The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study

Overview

Journal Oncology

Specialty Oncology

Date 2022 Oct 3

PMID 36191562

Authors

Tae-Woo Kim

Soon Woo Hwang

Kyeong Ok Kim

Jae Myung Cha

Young-Eun Joo

Young-Seok Cho

Affiliations

Soon will be listed here.

Abstract

Introduction: KRAS, BRAF, and DNA mismatch repair (MMR) mutations aid clinical decision-making for colorectal cancer (CRC) patients. To ensure accurate predictions, the prognostic utilities of these biomarkers and their combinations must be individualized for patients with various TNM stages.

Methods: Here, we retrospectively analyzed the clinicopathological features of 904 Korean CRC patients who underwent CRC surgery in three teaching hospitals from 2011 to 2013; we also assessed the prognostic utilities of KRAS, BRAF, and MMR mutations in these patients.

Results: The overall frequencies of KRAS and BRAF mutations were 35.8% and 3.2%, respectively. Sixty-nine patients (7.6%) lacking expression of ≥1 MMR protein were considered MMR protein deficient (MMR-D); the remaining patients were considered MMR protein intact. KRAS mutations constituted an independent risk factor for shorter overall survival (OS) in TNM stage I-IV and stage III patients. BRAF mutations were associated with shorter OS in TNM stage I-IV patients. MMR-D status was strongly positive prognostic in TNM stage I-II patients.

Discussion/conclusion: To our knowledge, this is the first multicenter study to explore the prognostic utilities of KRAS, BRAF, and MMR statuses in Korean CRC patients. Various combinations of KRAS, BRAF, and DNA MMR mutations serve as genetic signatures that affect tumor behavior; they are prognostic in CRC patients.

Citing Articles

Development and validation of a clinical prognostic model for BRAF V600E-mutated colorectal cancer patients based on pathological stage, microsatellite status, and primary tumor site.

Ou K, Liu X, Ma X, Yang L Front Oncol. 2024; 14:1461237.

PMID: 39464719 PMC: 11502291. DOI: 10.3389/fonc.2024.1461237.

References

Muller M, Ibrahim A, Arends M . Molecular pathological classification of colorectal cancer. Virchows Arch. 2016; 469(2):125-34. PMC: 4978761. DOI: 10.1007/s00428-016-1956-3. View

Murcia O, Juarez M, Rodriguez-Soler M, Hernandez-Illan E, Giner-Calabuig M, Alustiza M . Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS One. 2018; 13(9):e0203051. PMC: 6126803. DOI: 10.1371/journal.pone.0203051. View

Battaglin F, Naseem M, Lenz H, Salem M . Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018; 16(11):735-745. PMC: 7493692. View

Ahuja N, Mohan A, Li Q, Stolker J, Herman J, Hamilton S . Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res. 1997; 57(16):3370-4. View

Sinicrope F, Shi Q, Allegra C, Smyrk T, Thibodeau S, Goldberg R . Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2016; 3(4):472-480. PMC: 5498991. DOI: 10.1001/jamaoncol.2016.5469. View

Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D . Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009; 28(3):466-74. DOI: 10.1200/JCO.2009.23.3452. View

Salem M, Battaglin F, Goldberg R, Puccini A, Shields A, Arguello D . Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. Oncologist. 2019; 25(5):404-413. PMC: 7216442. DOI: 10.1634/theoncologist.2019-0552. View

Afrasanie V, Marinca M, Alexa-Stratulat T, Gafton B, Paduraru M, Adavidoaiei A . KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol. 2019; 53(3):265-274. PMC: 6765160. DOI: 10.2478/raon-2019-0033. View

Dedeurwaerdere F, Bm Claes K, Van Dorpe J, Rottiers I, Van der Meulen J, Breyne J . Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep. 2021; 11(1):12880. PMC: 8213758. DOI: 10.1038/s41598-021-91974-x. View

10.

Guo T, Wu Y, Tan C, Jin Y, Sheng W, Cai S . Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Int J Cancer. 2019; 145(6):1625-1634. PMC: 6771586. DOI: 10.1002/ijc.32489. View

11.

Bellio H, Fumet J, Ghiringhelli F . Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel). 2021; 13(9). PMC: 8124706. DOI: 10.3390/cancers13092201. View

12.

Hu J, Yan W, Xie L, Cheng L, Yang M, Li L . Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer. Medicine (Baltimore). 2016; 95(50):e5649. PMC: 5268058. DOI: 10.1097/MD.0000000000005649. View

13.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

14.

Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D . NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol. 2010; 19(3):157-63. PMC: 2929976. DOI: 10.1097/PDM.0b013e3181c93fd1. View

15.

Cushman-Vokoun A, Stover D, Zhao Z, Koehler E, Berlin J, Vnencak-Jones C . Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing. Clin Colorectal Cancer. 2013; 12(3):168-78. PMC: 4090139. DOI: 10.1016/j.clcc.2013.04.005. View

16.

Chen K, Xia G, Zhang C, Sun Y . Correlation between smoking history and molecular pathways in sporadic colorectal cancer: a meta-analysis. Int J Clin Exp Med. 2015; 8(3):3241-57. PMC: 4443048. View

17.

Zarkavelis G, Boussios S, Papadaki A, Katsanos K, Christodoulou D, Pentheroudakis G . Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017; 30(6):613-621. PMC: 5670280. DOI: 10.20524/aog.2017.0191. View

18.

Thanki K, Nicholls M, Gajjar A, Senagore A, Qiu S, Szabo C . Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. Int Biol Biomed J. 2017; 3(3):105-111. PMC: 5557054. View

19.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

20.

Pino M, Chung D . Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011; 5(3):385-99. DOI: 10.1586/egh.11.25. View